

Detect more with less

Maximize your insight from small biopsy samples

Discover **SOPHiA DDM™ RNAtarget Oncology Solution**, an end-to-end application to characterize complex genomic variants by combining a capture-based target enrichment kit with the analytical performance and advanced features of the SOPHiA DDM™ Platform.

Make the most of your precious biopsy samples with our all-in-one solution to detect and interpret novel fusions, SNVs, and Indels in major lung cancer biomarkers such as **EGFR (vIII exon skipping)**, **KRAS (G12C)**, **ALK**, **ROS1**, **BRAF (V600E)**, **NTRK**, **MET (exon 14 skipping)**, **RET**, **ERBB2** and **PD-L1**.

ALL NCCN Guidelines® recommended biomarkers for NSCLC¹ are covered



Low input amount

Set up to work with as little as **10ng RNA/tNA** to exploit fully scarce biopsy samples



Comprehensive variant detection

Designed to accurately detect **novel fusions** (partner-agnostic), **SNVs**, and **Indels**



Powered by SOPHiA DDM™

Easy variants **visualization and filtering** with access to the latest scientific evidence via **OncoPortal™ Plus**



Benefits of SOPHiA DDM™ RNAtarget Oncology Solution



Get the application built to meet your specific needs with our **customization** options and full Set-up program.



Streamline your workflow with a **1.5-day end-to-end protocol**, compatible with automation.



Accelerate your research with our powerful proprietary algorithms and versatile **SOPHiA DDM™ Platform**.

45 genes covered ○ SNVs/Indels ☆ Fusions

AKT1 ○	DPYD ○	FGFR2 ☆ ○	KIT ○	NTRK2 ☆ ○	RET ☆ ○
ALK ☆ ○	EGFR ☆ ○	FGFR3 ☆ ○	KRAS ○	NTRK3 ☆ ○	ROS1 ☆ ○
ATM ○	ERBB2 ○	FGFR4 ☆ ○	MAP2K1 ○	PALB2 ○	STK11 ○
BRAF ☆ ○	ERBB3 ○	FOXL2 ^a ○	MDM2 ○	PD-L1 ○	TERT ○
BRCA1 ○	ERBB4 ○	GNAS ○	MET ☆ ○	PDGFRA ○	TP53 ○
BRCA2 ○	ERG ☆	HRAS ○	NRAS ○	PIK3CA ○	
CTNNB1 ○	ESR1 ○	IDH1 ○	NRG1 ☆	PPARG ☆	
DDR2 ○	FGFR1 ☆ ○	IDH2 ○	NTRK1 ☆ ○	PTEN ○	

ADVANCED ANALYTICAL PERFORMANCES*

SOPHiA DDM™ RNAtarget Oncology Solution

shows excellent analytical performances with both RNA and tNA samples and provides experts with the required confidence in their NGS results.

SNV/Indel detection
LoD 5% VAF

99.80%
Sensitivity

99.99%
Specificity

Novel fusion detection
LoD 10 molecules

100%
Sensitivity


99.99%
Specificity

*Based on 50ng RNA samples sequenced on Illumina NextSeq®. Specificity for SNVs/Indels based on reference samples only. Data on file

Product Specifications

Panel size	45 genes covered 97kb
Sample type	FFPE and fresh frozen tissues
Starting material	Minimum: 10 ng RNA or tNA Recommended: 50ng
Sequencer compatibility	Illumina NextSeq® and MiSeq®
Multiplexing example for lung samples ^b	16 samples on MiSeq® v3 86 samples on NextSeq® 500/550 Mid Output
Product code	CS2535ILLRSRY07-32

Want to learn more?



Or contact us at:
info@sophiagenetics.com

SOPHiA GENETICS also offers the CE-IVD product, SOPHiA DDM™ Dx RNAtarget Oncology Solution^c

FFPE, formalin-fixed paraffin-embedded; Indels, Insertions/deletions; LoD, limit of detection; NCCN, National Comprehensive Cancer Network; NSCLC, Non-Small Cell Lung Cancer; RNA, ribonucleic acid; SNVs, single nucleotide variants; tNA, total nucleic acid. VAF, variant allele fraction. ^aExcluded from gene expression analysis. ^bRecommendation based on 3M reads and 1.5M fragments in a lung sample for 1000x coverage depth. Recommendations for other tissues, sequencing kits, and instruments are available upon request. ^cRefer to SOPHiA DDM™ Dx RNAtarget Oncology Solution webpage for product specifications and performance metrics.

¹ NCCN, NSCLC (v2.2023). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed April 13, 2023.

SOPHiA DDM™ RNAtarget Oncology Solution is for Research Use Only and is not intended for purposes other than research. SOPHiA DDM™ Dx RNAtarget Oncology Solution is available as CE-IVD products for In Vitro Diagnostic Use in Europe and Turkey.